secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2025-01-28T23:59:59+00:00
Accession:  0001725160-25-000006
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis restructures with 40% workforce cut, focuses WEE1 inhibitor, cash to late 2027
--------------------------------------------------------------------------------

- Approves workforce reduction of approx. 40%; substantially complete by Q2 2025.
- Expects $7.0-8.0M in one-time termination costs in Q1 2025.
- Believes cash runway extended into late 2027, beyond potential azenosertib data readout.
- Registration-enabling DENALI Part 2 data readout anticipated by end of 2026.
- Corporate event on Jan 29, 2025, to present azenosertib clinical data and regulatory update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000006/0001725160-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000006/zntl-20250122.htm
  HTML page:      https://secwatch.observer/filing/0001725160-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer